Ridwelski 2008.

Methods	Multicentre RCT 2 arms Quality score: B
Participants	n = 273 Median age: 62 years Metastatic disease: 90%
Interventions	DC: docetaxel 75 mg/m² + cisplatin 75 mg/m² d 1, repeated at 3 w FLC: 5‐FU 2000 mg/m² + leucovorin 500 mg/m² d 1, 8, 15, 22, 29, 36, repeated at 7 w + cisplatin 50 mg/m² d 1, 15, 29, repeated at 7 w (cisplatin omitted in FLC in cycle 4)
Outcomes	Median overall and hazard ratios for survival and time to progression 1‐year survival Tumour response Toxicity
Notes	Study currently published as abstract only. Information on final results provided by first author.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number tables
Allocation concealment (selection bias)	Low risk	Central
Incomplete outcome data (attrition bias) efficacy	Low risk	Analysis for all randomised and screened patients
Incomplete outcome data (attrition bias) safety	Low risk	Analysis for all randomised, screened and treated patients
Selective reporting (reporting bias)	Low risk	Report includes all expected outcomes
Other bias	Unclear risk	N/A
Blinded review of CT/MRI‐scans?	High risk	Per first author